Danaher acquires AB SCIEX and Molecular Devices

Danaher Corporation (NYSE: DHR) announced today that it has completed the previously announced acquisition of AB SCIEX and Molecular Devices.  AB SCIEX is a leading designer and manufacturer of mass spectrometers, highly sensitive and sophisticated instruments used by researchers and clinicians to identify and quantify specific molecules in complex samples.  

Molecular Devices supplies high-performance bio-analytical instrumentation systems and consumables that accelerate and improve research productivity and effectiveness in life science research and drug discovery.  


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Danaher. (2019, June 18). Danaher acquires AB SCIEX and Molecular Devices. News-Medical. Retrieved on April 20, 2024 from https://www.news-medical.net/news/20100201/Danaher-acquires-AB-SCIEX-and-Molecular-Devices.aspx.

  • MLA

    Danaher. "Danaher acquires AB SCIEX and Molecular Devices". News-Medical. 20 April 2024. <https://www.news-medical.net/news/20100201/Danaher-acquires-AB-SCIEX-and-Molecular-Devices.aspx>.

  • Chicago

    Danaher. "Danaher acquires AB SCIEX and Molecular Devices". News-Medical. https://www.news-medical.net/news/20100201/Danaher-acquires-AB-SCIEX-and-Molecular-Devices.aspx. (accessed April 20, 2024).

  • Harvard

    Danaher. 2019. Danaher acquires AB SCIEX and Molecular Devices. News-Medical, viewed 20 April 2024, https://www.news-medical.net/news/20100201/Danaher-acquires-AB-SCIEX-and-Molecular-Devices.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Southern Implants, Keystone announce merger agreement